LEGNLegend Biotech Corp

Nasdaq legendbiotech.com


$ 43.61 $ -1.93 (-4.24 %)    

Tuesday, 11-Jun-2024 10:42:11 EDT
QQQ $ 464.77 $ 1.27 (0.27 %)
DIA $ 387.26 $ -0.11 (-0.03 %)
SPY $ 534.28 $ 0.20 (0.04 %)
TLT $ 91.14 $ 0.08 (0.09 %)
GLD $ 214.15 $ -0.27 (-0.13 %)
$ 45.54
$ 45.14
$ 43.55 x 100
$ 43.60 x 200
$ 43.28 - $ 45.25
$ 38.60 - $ 77.32
738,333
na
16.57B
$ 0.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-73-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price t...

Core News & Articles

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-73

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

 deutsche-bank-initiates-coverage-on-legend-biotech-with-buy-rating-announces-price-target-of-60

Deutsche Bank analyst James Shin initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and announces Price Ta...

 rbc-capital-maintains-outperform-on-legend-biotech-raises-price-target-to-86

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-86

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price targe...

 legend-biotech-q1-2024-gaap-eps-016-beats-034-estimate-sales-93991m-miss-152631m-estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

 legend-biotech-announces-carvykti-approved-by-the-european-commission-for-second-line-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

 fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

 scotiabank-upgrades-legend-biotech-to-sector-outperform-maintains-price-target-to-65

Scotiabank analyst George Farmer upgrades Legend Biotech (NASDAQ:LEGN) from Sector Perform to Sector Outperform and maintain...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-87-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...